Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442194 · ClinicalTrials.gov registry record
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,076
- Enrollment target
NCT01442194 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,076 participants.
The verdict
NCT01442194 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,076 participants
- Enrollment target
Study Summary
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Interventions
- DRUG Fingolimod
- DRUG other disease-modifying therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,076 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2020-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442194
The ClinicalTrials.gov registry entry for NCT01442194 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,076 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fingolimod is the first listed.
NCT01442194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442194 about?
NCT01442194 is a clinical study titled "Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies". The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall sa...
What is the current status of trial NCT01442194?
This trial is currently completed. The enrollment target is 3,076 participants. The study started on 2011-08-01. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT01442194?
The interventions under investigation include: Fingolimod (DRUG), other disease-modifying therapy (DRUG).
Who is sponsoring clinical trial NCT01442194?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.